KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short term Debt: 2024-2025

Historic Short term Debt for Alnylam Pharmaceuticals (ALNY) over the last 1 years, with Sep 2025 value amounting to $121.3 million.

  • Alnylam Pharmaceuticals' Short term Debt was N/A to $121.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year change of. This contributed to the annual value of $93.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Short term Debt is $121.3 million, which was up 0.41% from $120.8 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Short term Debt's 5-year high stood at $121.3 million during Q3 2025, with a 5-year trough of $93.8 million in Q4 2024.
  • Moreover, its 2-year median value for Short term Debt was $119.5 million (2025), whereas its average is $113.5 million.